Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

1 Day VRTX -0.71% DJIA 0.38% S&P 500 0.53% Health Care/Life Sciences 0.19% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new ...

As a first time visitor, when you visit the Business Standard website, you come across some articles denoted with a key prefixed ... use you may not Download and archive or save copies of epaper in ...

A man suspected to have contracted GBS has died in Maharashtra's Solapur district, while the number of cases of the immunological nerve disorder in Pune has crossed 100-mark ...

This advertisement has not loaded yet, but your article continues below.